LB Pharmaceuticals Inc Common Stock LBRX Business Segments
| TTM Q4 '25 | TTM Q3 '25 | TTM Q2 '25 | TTM Q1 '25 | ||
|---|---|---|---|---|---|
| Direct Research And Development Expenses by Product | |||||
| Clinical Trial | $4.73M-66.6% | $14.14M-40.0% | $23.55M-28.6% | $32.96M-22.2% | |
| Preclinical | $129K-76.9% | $558K-43.5% | $987K-30.3% | $1.42M-23.3% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- How does LB Pharmaceuticals Inc Common Stock break its business down?
- LB Pharmaceuticals Inc Common Stock (LBRX) reports direct research and development expenses by product across 6 parts — Bipolar Depression Programs, Clinical Trial, Formulation And CMC, Preclinical And Other Direct Expenses and Preclinical. Each is extracted from the segment footnotes and tracked over time.
- Where does LB Pharmaceuticals Inc Common Stock's segment data come from?
- Segment breakdowns are pulled from the segment footnotes in LB Pharmaceuticals Inc Common Stock's SEC filings (the XBRL dimensional tags), so every line ties back to a reported figure. Switch between quarterly, annual, and TTM, or open any segment for its full history.